Target Name: IL17F
NCBI ID: G112744
Review Report on IL17F Target / Biomarker Content of Review Report on IL17F Target / Biomarker
IL17F
Other Name(s): IL17F variant X1 | Interleukin 17F | Interleukin-17F, transcript variant X1 | IL-26 | IL-17F | IL17A | IL17F_HUMAN | CANDF6 | Cytokine ML-1 | interleukin 17F | Interleukin-17F | Interleukin-17F (isoform X1) | ML-1 | cytokine ML-1 | ML1

IL17F Variant X1: A Promising Drug Target for Immune and Inflammatory Disorders

IL17F (Interleukin-17) is a cytokine that plays a crucial role in the immune response and inflammation. It is a cytokine that is expressed in a variety of tissues, including tissues that are involved in the immune response, such as the lungs, ears, and skin. It is also involved in the regulation of inflammation, and has been shown to have anti-inflammatory effects.

The IL17F variant X1 is a specific variant of the IL17F gene that has been shown to have unique properties. This variant has been shown to have increased activity compared to the wild-type form of the gene. It is also has been shown to be involved in the regulation of inflammation and has been shown to have anti-inflammatory effects.

One of the key properties of IL17F is its ability to stimulate the production of immune cells, such as T-cells and B-cells. This is important for the immune system to defend against infections and to fight off inflammation. Studies have shown that IL17F variant X1 can significantly enhance the production of immune cells compared to the wild-type form of the gene.

Another important property of IL17F is its ability to regulate inflammation. Inflammation is a natural response of the immune system, but when it becomes out of control, it can cause pain, swelling, and damage to tissues. IL17F variant X1 has been shown to have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines.

IL17F variant X1 has also been shown to have effects on pain perception. Studies have shown that IL17F variant X1 can significantly reduce the production of pain-sensitive neuropeptides, which can help to alleviate pain.

Another potential drug target for IL17F variant X1 is its role in the regulation of skin health.Studies have shown that IL17F variant X1 can significantly improve the skin health of individuals with dry skin by increasing the production of skin-rejuvenating cytokines.

In conclusion, IL17F variant X1 is a promising drug target and biomarker due to its unique properties, including its ability to stimulate the production of immune cells, regulate inflammation and have anti-inflammatory effects, and improve skin health. Further studies are needed to fully understand the potential of IL17F variant X1 as a drug.

Protein Name: Interleukin 17F

Functions: Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:21350122). IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:18684971, PubMed:21350122, PubMed:11591732, PubMed:11591768, PubMed:17911633, PubMed:11574464, PubMed:28827714). IL17A-IL17F is primarily involved in host defense against extracellular bacteria and fungi by inducing neutrophilic inflammation (By similarity). As signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway (PubMed:32187518). Via IL17RC induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Likely via IL17RC, promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression (By similarity). Regulates the composition of intestinal microbiota and immune tolerance by inducing antimicrobial proteins that specifically control the growth of commensal Firmicutes and Bacteroidetes (By similarity)

The "IL17F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL17F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2